Research Topics
Genomes and Genes | R HalabanSummaryAffiliation: Yale University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"Paolo A Ascierto
Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
J Transl Med 9:32. 2011..Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies...
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032Jill C Rubinstein
Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA
J Transl Med 8:67. 2010..Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations...
Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanomaJill C Rubinstein
Interdepartmental Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT 06520, USA
BMC Med Genomics 3:4. 2010..The cytosine analog 5-aza-2'-deoxycytidine (decitabine) induces genomic hypomethylation by inhibiting DNA methyltransferase, and is an example of an epigenetic agent that is thought to act by up-regulating silenced genes...
Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsiesFabio Parisi
Department of Pathology and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA
BMC Genomics 12:230. 2011..However, heterogeneity of tumor subclones dramatically complicates the task of detecting aberrations...
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implicationsRuth Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, United States of America
PLoS ONE 4:e4563. 2009..Our integrative analysis show that improved therapy can be achieved by comprehensive analysis of cancer cells, identified biomarkers for patient's selection and monitoring response, as well as targets for improved combination therapy...
Pigmentation in melanomas: changes manifesting underlying oncogenic and metabolic activitiesRuth Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520 8059, USA
Oncol Res 13:3-8. 2002..These lesions might have encountered anaerobic conditions, and have adapted to the reduced oxygen by enhanced glycolysis, leading to extracellular acidification and activation of V-ATPase...
Coexpression of wild-type tyrosinase enhances maturation of temperature-sensitive tyrosinase mutantsRuth Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520 8059, USA
J Invest Dermatol 119:481-8. 2002..The results may explain the variation in pigmentation and the development of pigment later in life in patients carrying different mutant alleles of oculocutaneous albinism 1B...
Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathwayRuth Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
J Biol Chem 277:14821-8. 2002....
Proper folding and endoplasmic reticulum to golgi transport of tyrosinase are induced by its substrates, DOPA and tyrosineR Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
J Biol Chem 276:11933-8. 2001..Loss of pigmentation, therefore, in tyrosinase-positive melanoma cells is a consequence of tumor-induced metabolic changes that suppress tyrosinase activity and DOPA production within these cells...
Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinismR Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA
Proc Natl Acad Sci U S A 97:5889-94. 2000..From these results we concluded that albinism, at least in part, is an ER retention disease...
The regulation of normal melanocyte proliferationR Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520 8059, USA
Pigment Cell Res 13:4-14. 2000..Molecular events that disrupt this tight control of pocket proteins and cause their inactivation, increase E2F transcriptional activity and confer autonomous growth on melanocytes...
Deregulated E2F transcriptional activity in autonomously growing melanoma cellsR Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520 8059, USA
J Exp Med 191:1005-16. 2000....
Melanoma cell autonomous growth: the Rb/E2F pathwayR Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA
Cancer Metastasis Rev 18:333-43. 1999..Since all pocket proteins are regulated by CDKs activity, it is likely that agents that inhibit this class of enzymes will be effective in treating melanoma patients...
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cellsRuth Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA
Pigment Cell Melanoma Res 23:190-200. 2010..The results suggest that the drug can confer an advantage to BRAF(WT) primary and metastatic tumor cells in vivo and provide markers for monitoring clinical responses...
Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cellsR Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA
Proc Natl Acad Sci U S A 94:6210-5. 1997..Proteolysis of tyrosinase by proteasomes is consistent with the production of antigenic tyrosinase peptides that are presented to the immune system by major histocompatibility complex class I molecules...
Rb/E2F: a two-edged sword in the melanocytic systemRuth Halaban
Department of Dermatology, Yale University School of Medicine, 15 York Street, P O Box 208059, New Haven, CT, 06520 8059, USA
Cancer Metastasis Rev 24:339-56. 2005..In addition, the high E2F transcriptional activity in melanoma cells can be exploited to deliver cytotoxic molecules specifically to tumors, sparing the normal tissues...
Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p16INK4A or p21WAF1/CIP1R Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Oncogene 16:2489-501. 1998..Thus, mechanisms other than the loss of p16INK4A or p21WAF1/CIP1 that activate E2F may play an important role in melanomas...
Murine and human b locus pigmentation genes encode a glycoprotein (gp75) with catalase activityR Halaban
Department of Dermatology, Yale University School of Medicine, New Haven, CT 06510
Proc Natl Acad Sci U S A 87:4809-13. 1990....
UV-induced ubiquitination of RNA polymerase II: a novel modification deficient in Cockayne syndrome cellsD B Bregman
Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA
Proc Natl Acad Sci U S A 93:11586-90. 1996..Alternatively, these findings may reflect a role played by the CSA and CSB gene products in transcription...
Regulation of fibroblast growth factor 2 expression in melanoma cells by the c-MYB proto-oncoproteinM R Miglarese
Department of Cancer, Immunology and Infectious Diseases, Pfizer Central Research, Groton, Connecticut 06340, USA
Cell Growth Differ 8:1199-210. 1997..We suggest that c-MYB contributes to FGF-2-mediated autocrine growth of melanomas by indirectly regulating the FGF-2 promoter...
Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibodyM B Flick
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut 06520 8040, USA
Oncogene 14:2553-61. 1997..This data represents the first direct evidence of in vivo phosphorylation of CSF-1R in human breast carcinomas...
A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanomaS E Godshalk
Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA
Oncogene 30:1542-50. 2011..This work identifies a novel genetic marker for increased heritable risk of melanoma...
Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray studyHarriet M Kluger
Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
Melanoma Res 14:207-10. 2004..Our findings suggest that drugs that specifically target Her2/neu are not likely to be useful for the treatment of metastatic melanoma or as adjuvant therapy for melanoma patients at high risk for recurrence...
The tyrphostin AG1024 accelerates the degradation of phosphorylated forms of retinoblastoma protein (pRb) and restores pRb tumor suppressive function in melanoma cellsMaria von Willebrand
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Cancer Res 63:1420-9. 2003..Thus, inhibition of melanoma cell proliferation by AG1024 is mediated by inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase 2 signaling and activation of pRb by a mechanism involving protein degradation...
Tyrosinase maturation and oligomerization in the endoplasmic reticulum require a melanocyte-specific factorEdwin Francis
Department of Biochemistry and Molecular Biology, Program in Molecular and Cellular Biology, University of Massachusetts, Amherst, Massachusetts 01003, USA
J Biol Chem 278:25607-17. 2003..These findings suggested that oligomerization is a step in proper TYR maturation within the ER that requires melanocyte-specific factors...
Carbohydrates act as sorting determinants in ER-associated degradation of tyrosinaseSherri Svedine
Department of Biochemistry and Molecular Biology, Program in Molecular and Cellular Biology, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA
J Cell Sci 117:2937-49. 2004....
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanomaMary M McCarthy
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Clin Cancer Res 12:3856-63. 2006..We assessed TRAIL-R1 and TRAIL-R2 expression patterns in a large cohort of melanomas and benign nevi...
Melanocyte and keratinocyte carcinogenesis: p53 family protein activities and intersecting mRNA expression profilesMolly Kulesz-Martin
Department of Dermatology, Oregon Health and Science University, Portland, Oregon 97239, USA
J Investig Dermatol Symp Proc 10:142-52. 2005..Thus, clonal lineage mouse models representing early through late cancer progression stages may inform the focus on early, potentially causal events from microarray studies of human cancers, facilitating prognosis and molecular therapy...
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survivalAaron J Berger
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Cancer Res 63:8103-7. 2003..Moreover, our findings suggest that ATF2 might be a useful prognostic marker in early-stage melanoma...
Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcomeAaron J Berger
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Cancer Res 64:8767-72. 2004....
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomasKeith Hoek
Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, 15 York Street, New Haven, CT 06520-8059, USA
Cancer Res 64:5270-82. 2004..These results provide a comprehensive view of changes in advanced melanoma relative to normal melanocytes and reveal new targets that can be used in assessing prognosis, staging, and therapy of melanoma patients...
Novel tyramide-based tyrosinase assay for the detection of melanoma cells in cytological preparationsCesar Angeletti
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Diagn Cytopathol 31:33-7. 2004..This method may be a useful ancillary procedure for the resolution of challenging melanoma cases...
Rab33A: characterization, expression, and suppression by epigenetic modificationElaine Cheng
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520-8059, USA
J Invest Dermatol 126:2257-71. 2006..This information is important for understanding carcinogenesis as well as other aberrant processes because Rab33A may have an important role in disorders involving X-chromosome-linked genes associated with vesicular transport...
Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesionsBonnie E Gould Rothberg
Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
Mod Pathol 21:1121-9. 2008..80 for distinguishing benign nevi from malignant melanomas. On the basis of this preliminary study, we propose that the ratio of nuclear to non-nuclear HMB45 staining may be useful for diagnostic challenges in melanocytic lesions...
Roadmap for new opportunities in melanoma researchMeenhard Herlyn
Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA 19104, USA
Semin Oncol 34:566-76. 2007..This group provides recommendations for both short- and long-term strategies that build on research strengths and opportunities established by the many members of the research community...
Research Grants
- Epigenetic Chromatin Changes as Melanoma MarkersRuth Halaban; Fiscal Year: 2006..Altogether, the results are likely to generate a novel marker(s) that can be used to assess propensity for malignant transformation, tumor progression and/or sensitivity to chemotherapeutic drugs that target chromatin conformation. ..
- PROLIFERATION & MALIGNANT TRANSFORMATION OF MELANOCYTESRuth Halaban; Fiscal Year: 2004..Our functional studies may provide a basis for the design of new therapeutical agents for the treatment of patients with metastatic melanomas. ..
- 2003 Conference Pan-American Society Pigment Cell ReseaRuth Halaban; Fiscal Year: 2003..3. To provide partial support to students and junior faculty to attend the meeting. They request funds for the 2003 meeting as well as for the 2 subsequent PASPCR annual meetings in years 2004 and 2006. ..
